FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1981468497> ?p ?o ?g. }

• W1981468497 endingPage "S28" @default.
• W1981468497 startingPage "S20" @default.
• W1981468497 abstract "This study was undertaken to investigate whether budesonide 4001 microg twice daily (Chiesi Farmaceutici S.p.A.) given with the HFA-134a propellant is equivalent in efficacy and safety to the same dose regimen delivered with the marketed CFC product in adult asthmatics with mild to moderate persistent asthma; the effects of budesonide HFA 800 microg once daily were also studied. After a 2-week run-in, a total number of 98, 103 and 97 patients were assigned to the 12-week treatment with budesonide given with HFA or CFC twice daily (morning and evening), or HFA once daily (morning), respectively. The main outcome variable morning PEFR, as well as evening PEFR and clinical symptoms (day-time and night-time asthma attacks, number of asthma-induced night-time awakenings and overall symptoms' scores) were measured daily by patients. Other standard pulmonary function testing were measured at clinic visits. A blood sample for morning serum dosing (8.00-10.00 AM) was taken at baseline and at endpoint. Adverse events and vital signs were also recorded. Significant improvements at endpoint in morning and evening PEFR, as well as in clinic PEFR and MEF50, were observed in both the twice daily groups only. An exact proof of equivalence between HFA and CFC given twice daily was demonstrated for the primary parameters, morning PEFR (equivalence pre-defined limits were +/- 40.27 l/min, difference between means = 4.0 l/min and 95% CI -6.9-14.9) and secondary parameters as evening PEFR: (limits +/- 40.19 l/min, difference between means = 2.1 l/min and 95% Confidence interval (CI) -9.4-13.5) and FEV1 (limits +/- 0.27 l, difference between means = 0.0 l and 95% CI -0.11-0.10). Less evident (but within limits) proofs of equivalence were shown in the comparisons with the once daily group. No substantial differences between the three groups were observed for the other efficacy variables, including symptoms and use of rescue salbutamol, which significantly improved over the run-in values in all groups. Minimal and non-significant decreases over pre-treatment values were observed in the three groups for morning serum cortisol levels: the analysis of individual data has shown a better outcome in the HFA twice daily regimen, compared with the other two groups. Again, a similar amount of patients in both the twice daily groups reported drug-related adverse events, which were more frequent in the once daily HFA group. Therefore, the results of this study have shown that inhaled budesonide given with new HFA-134a propellant can replace microgram-equivalent doses of the corresponding marketed CFC product when given twice daily. An overall maintainment and an unchanged risk-benefit ratio has emerged for budesonide HFA given once daily, which was however slightly inferior compared with the standard twice daily regimens." @default.
• W1981468497 created "2016-06-24" @default.
• W1981468497 creator A5001308400 @default.
• W1981468497 creator A5012247292 @default.
• W1981468497 creator A5065401575 @default.
• W1981468497 creator A5088780764 @default.
• W1981468497 date "2003-11-01" @default.
• W1981468497 modified "2023-09-30" @default.
• W1981468497 title "Efficacy and safety of inhaled budesonide delivered once or twice daily via HFA-134a in mild to moderate persistent asthma in adult patients. Comparison with budesonide CFC" @default.
• W1981468497 cites W1973482252 @default.
• W1981468497 cites W1975409885 @default.
• W1981468497 cites W1981055046 @default.
• W1981468497 cites W1985715587 @default.
• W1981468497 cites W1987262495 @default.
• W1981468497 cites W1997319024 @default.
• W1981468497 cites W2008576776 @default.
• W1981468497 cites W2013860817 @default.
• W1981468497 cites W2024714794 @default.
• W1981468497 cites W2045994527 @default.
• W1981468497 cites W2069091142 @default.
• W1981468497 cites W2166055237 @default.
• W1981468497 cites W2994597783 @default.
• W1981468497 doi "https://doi.org/10.1016/j.rmed.2003.10.001" @default.
• W1981468497 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14753248" @default.
• W1981468497 hasPublicationYear "2003" @default.
• W1981468497 type Work @default.
• W1981468497 sameAs 1981468497 @default.
• W1981468497 citedByCount "15" @default.
• W1981468497 countsByYear W19814684972012 @default.
• W1981468497 crossrefType "journal-article" @default.
• W1981468497 hasAuthorship W1981468497A5001308400 @default.
• W1981468497 hasAuthorship W1981468497A5012247292 @default.
• W1981468497 hasAuthorship W1981468497A5065401575 @default.
• W1981468497 hasAuthorship W1981468497A5088780764 @default.
• W1981468497 hasBestOaLocation W19814684971 @default.
• W1981468497 hasConcept C121332964 @default.
• W1981468497 hasConcept C126322002 @default.
• W1981468497 hasConcept C1276947 @default.
• W1981468497 hasConcept C187212893 @default.
• W1981468497 hasConcept C19720800 @default.
• W1981468497 hasConcept C197934379 @default.
• W1981468497 hasConcept C2776042228 @default.
• W1981468497 hasConcept C2776136866 @default.
• W1981468497 hasConcept C2776476923 @default.
• W1981468497 hasConcept C2776804153 @default.
• W1981468497 hasConcept C2777288759 @default.
• W1981468497 hasConcept C42219234 @default.
• W1981468497 hasConcept C71924100 @default.
• W1981468497 hasConceptScore W1981468497C121332964 @default.
• W1981468497 hasConceptScore W1981468497C126322002 @default.
• W1981468497 hasConceptScore W1981468497C1276947 @default.
• W1981468497 hasConceptScore W1981468497C187212893 @default.
• W1981468497 hasConceptScore W1981468497C19720800 @default.
• W1981468497 hasConceptScore W1981468497C197934379 @default.
• W1981468497 hasConceptScore W1981468497C2776042228 @default.
• W1981468497 hasConceptScore W1981468497C2776136866 @default.
• W1981468497 hasConceptScore W1981468497C2776476923 @default.
• W1981468497 hasConceptScore W1981468497C2776804153 @default.
• W1981468497 hasConceptScore W1981468497C2777288759 @default.
• W1981468497 hasConceptScore W1981468497C42219234 @default.
• W1981468497 hasConceptScore W1981468497C71924100 @default.
• W1981468497 hasLocation W19814684971 @default.
• W1981468497 hasLocation W19814684972 @default.
• W1981468497 hasOpenAccess W1981468497 @default.
• W1981468497 hasPrimaryLocation W19814684971 @default.
• W1981468497 hasRelatedWork W1965285681 @default.
• W1981468497 hasRelatedWork W2027296386 @default.
• W1981468497 hasRelatedWork W2063656508 @default.
• W1981468497 hasRelatedWork W2099545157 @default.
• W1981468497 hasRelatedWork W2114437823 @default.
• W1981468497 hasRelatedWork W2144458251 @default.
• W1981468497 hasRelatedWork W2237516968 @default.
• W1981468497 hasRelatedWork W2410860778 @default.
• W1981468497 hasRelatedWork W2805897484 @default.
• W1981468497 hasRelatedWork W2970568810 @default.
• W1981468497 hasVolume "97" @default.
• W1981468497 isParatext "false" @default.
• W1981468497 isRetracted "false" @default.
• W1981468497 magId "1981468497" @default.
• W1981468497 workType "article" @default.